AR093515A1 - Triazolopirazinas - Google Patents
TriazolopirazinasInfo
- Publication number
- AR093515A1 AR093515A1 ARP130104230A ARP130104230A AR093515A1 AR 093515 A1 AR093515 A1 AR 093515A1 AR P130104230 A ARP130104230 A AR P130104230A AR P130104230 A ARP130104230 A AR P130104230A AR 093515 A1 AR093515 A1 AR 093515A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- optionally
- substituted
- groups
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/49—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton
- C07C211/50—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring having at least two amino groups bound to the carbon skeleton with at least two amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) en donde R¹ es -alquilo C₁₋₃ o -haloalquilo C₁₋₃; R² está seleccionado de -NHR⁴, -alquilo C₁₋₅, -haloalquilo C₁₋₅, halógeno y -S-alquilo C₁₋₃; R³ es un heteroarilo de 5 - 12 miembros, cuyo grupo está sustituido con -X-R¹⁰ y que opcionalmente también está sustituido con uno o varios grupos seleccionados de R⁹; R⁴ está seleccionado de -alquilo C₁₋₅ y heterocicloalquilo de 5 - 12 miembros, cuyo heterocicloalquilo puede estar opcionalmente sustituido con uno o varios grupos seleccionados de R⁵; R⁵ está seleccionado de -alquilo C₁₋₅, -haloalquilo C₁₋₅ y -alquilen C₁₋₃-O-alquilo C₁₋₃; R⁹ está seleccionado de -alquilo C₁₋₅, -O-alquilo C₁₋₅, -N(alquilo C₁₋₅)₂, halógeno, -alquilen C₁₋₃-O-alquilo C₁₋₃, -alquilen C₁₋₅-N(-alquilo C₁₋₅, -alquilo C₁₋₅), heterocicloalquilo de 5 - 12 miembros, en donde el grupo heterocicloalquilo puede estar opcionalmente sustituido uno o varios grupos seleccionados, de modo independiente, de =O, -alquilo C₁₋₃ o R⁹ está seleccionado de -arilo C₆₋₁₀ y heteroarilo de 5 - 12 miembros, en donde los grupos arilo y heteroarilo pueden estar opcional e independientemente sustituidos con uno o varios grupos seleccionados de halógeno, -alquilo C₁₋₃, -O-alquilo C₁₋₃, -haloalquilo C₁₋₃, -O-haloalquilo C₁₋₃, -N(alquilo C₁₋₅, alquilo C₁₋₅) y -NH-alquilo C₁₋₅; X es -alquilen C₁₋₃- u -O-; R¹⁰ es -arilo C₆₋₁₀ o heteroarilo de 5 - 12 miembros, cada uno de cuyos grupos puede estar opcionalmente sustituido uno ó varios grupos seleccionados de halógeno, -alquilo C₁₋₃, -O-alquilo C₁₋₃, -haloalquilo C₁₋₃, -O-haloalquilo C₁₋₃; en donde los compuestos de la fórmula (1) pueden estar opcionalmente presentes en forma de sales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12192987 | 2012-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093515A1 true AR093515A1 (es) | 2015-06-10 |
Family
ID=47177838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104230A AR093515A1 (es) | 2012-11-16 | 2013-11-15 | Triazolopirazinas |
Country Status (38)
Country | Link |
---|---|
US (3) | US9266891B2 (es) |
EP (1) | EP2925761B1 (es) |
JP (1) | JP5959754B2 (es) |
KR (1) | KR102190087B1 (es) |
CN (2) | CN104870448B (es) |
AP (1) | AP2015008418A0 (es) |
AR (1) | AR093515A1 (es) |
AU (1) | AU2013346809B9 (es) |
BR (1) | BR112015011158B1 (es) |
CA (1) | CA2891193C (es) |
CL (1) | CL2015001250A1 (es) |
CY (1) | CY1119387T1 (es) |
DK (1) | DK2925761T3 (es) |
EA (1) | EA029051B1 (es) |
ES (1) | ES2641465T3 (es) |
GE (1) | GEP201706624B (es) |
HK (1) | HK1210169A1 (es) |
HR (1) | HRP20171474T1 (es) |
HU (1) | HUE034467T2 (es) |
IL (1) | IL238400A (es) |
LT (1) | LT2925761T (es) |
MA (1) | MA38099B1 (es) |
ME (1) | ME02857B (es) |
MX (1) | MX363587B (es) |
MY (1) | MY191358A (es) |
NZ (1) | NZ707203A (es) |
PE (1) | PE20151023A1 (es) |
PH (1) | PH12015501074B1 (es) |
PL (1) | PL2925761T3 (es) |
PT (1) | PT2925761T (es) |
RS (1) | RS56333B1 (es) |
SG (1) | SG11201503856XA (es) |
SI (1) | SI2925761T1 (es) |
TN (1) | TN2015000187A1 (es) |
TW (1) | TWI619717B (es) |
UA (1) | UA114739C2 (es) |
UY (1) | UY35142A (es) |
WO (1) | WO2014076237A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9266891B2 (en) * | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
US9428513B2 (en) * | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
GB201321737D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
CN105669733A (zh) * | 2016-01-29 | 2016-06-15 | 上海毕路得医药科技有限公司 | 一种1-甲基-1h-吡唑-3-硼酸频哪醇酯的合成方法 |
AU2017359288A1 (en) * | 2016-11-14 | 2019-05-30 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer |
CN109111437B (zh) * | 2017-06-22 | 2022-03-04 | 中国科学院广州生物医药与健康研究院 | 一种苯并[d]异恶唑类化合物及其制备方法和应用 |
EP3654978A4 (en) | 2017-07-18 | 2021-03-31 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSIN ANTAGONISTS |
BR112020000962A2 (pt) | 2017-07-18 | 2020-07-14 | Nuvation Bio Inc. | compostos de 1,8-naftiridinona e usos dos mesmos |
CN111629725A (zh) * | 2018-01-25 | 2020-09-04 | 勃林格殷格翰国际有限公司 | 急性骨髓性白血病的组合治疗 |
CA3095760A1 (en) | 2018-04-19 | 2019-10-24 | Ember Technologies, Inc. | Portable cooler with active temperature control |
CN108794484B (zh) * | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | [1,2,4]三唑并[4,3-a]吡嗪衍生物、其药物组合物、制备方法和应用 |
US11192900B2 (en) | 2018-10-30 | 2021-12-07 | Nuvation Bio Inc. | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors |
JP7430728B2 (ja) | 2019-01-11 | 2024-02-13 | エンバー テクノロジーズ, インコーポレイテッド | 能動的温度制御を備える可搬式冷却器 |
US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
MX2021008650A (es) | 2019-01-18 | 2021-11-03 | Nuvation Bio Inc | Compuestos heterociclicos como antagonistas de adenosina. |
JP2022539116A (ja) | 2019-06-25 | 2022-09-07 | エンバー テクノロジーズ, インコーポレイテッド | 携帯型クーラー |
US11668508B2 (en) | 2019-06-25 | 2023-06-06 | Ember Technologies, Inc. | Portable cooler |
US11162716B2 (en) | 2019-06-25 | 2021-11-02 | Ember Technologies, Inc. | Portable cooler |
WO2021003310A1 (en) | 2019-07-02 | 2021-01-07 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
CN112470190A (zh) * | 2019-09-25 | 2021-03-09 | 深透医疗公司 | 用于改进低剂量体积对比增强mri的系统和方法 |
WO2021065980A1 (ja) | 2019-09-30 | 2021-04-08 | 協和キリン株式会社 | Bet分解剤 |
WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
WO2022184664A1 (en) * | 2021-03-02 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
EP4313308A1 (en) * | 2021-03-26 | 2024-02-07 | Cedilla Therapeutics, Inc. | Tead inhibitors and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3915968A (en) | 1973-09-21 | 1975-10-28 | Lepetit Spa | Triazolopyridazines |
BR9814628A (pt) * | 1997-11-11 | 2001-11-27 | Ono Pharmaceutical Co | Derivados de pirazina fundidos |
ME02736B (me) | 2005-12-21 | 2017-10-20 | Janssen Pharmaceutica Nv | Triazolopiridazini kao modulatori tirozin kinaze |
WO2008109104A1 (en) | 2007-03-07 | 2008-09-12 | The Regents Of The University Of California | Bivalent inhibitors of akt protein kinase |
JP2010524953A (ja) | 2007-04-17 | 2010-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | 縮合ヘテロ環11−β−ヒドロキシステロイドデヒドロゲナーゼI型阻害剤 |
KR20100099742A (ko) | 2007-12-21 | 2010-09-13 | 아스트라제네카 아베 | 안드로겐 수용체 관련 병태의 치료에서 사용하기 위한 이환식 유도체 |
US8476260B2 (en) * | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
EP3037423B1 (en) | 2009-11-05 | 2017-09-20 | Glaxosmithkline LLC | Novel benzodiazepine compound |
CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
ES2526671T3 (es) | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
DE102011082013A1 (de) * | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
KR20150007349A (ko) | 2012-05-11 | 2015-01-20 | 애브비 인코포레이티드 | Nampt 억제제 |
RU2015115634A (ru) * | 2012-09-28 | 2016-11-20 | Онкоэтикс Гмбх | Фармацевтический состав, содержащий соединения тиенотриазолодиазепина |
US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
US9266891B2 (en) * | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
EP2978757B1 (en) | 2013-03-27 | 2017-02-08 | Boehringer Ingelheim International GmbH | Indolinone analogues as brd4 inhibitors |
EP2978758B1 (en) | 2013-03-27 | 2017-02-08 | Boehringer Ingelheim International GmbH | Dihydroquinazolinone analogues as brd4 inhibitors |
US20150051208A1 (en) | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
US9428513B2 (en) | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
US9428515B2 (en) | 2014-05-09 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives |
-
2013
- 2013-11-11 US US14/076,510 patent/US9266891B2/en active Active
- 2013-11-15 EA EA201500536A patent/EA029051B1/ru not_active IP Right Cessation
- 2013-11-15 PT PT137898334T patent/PT2925761T/pt unknown
- 2013-11-15 DK DK13789833.4T patent/DK2925761T3/en active
- 2013-11-15 NZ NZ70720313A patent/NZ707203A/en unknown
- 2013-11-15 MX MX2015005953A patent/MX363587B/es unknown
- 2013-11-15 CN CN201380059254.4A patent/CN104870448B/zh active Active
- 2013-11-15 JP JP2015542274A patent/JP5959754B2/ja active Active
- 2013-11-15 KR KR1020157012600A patent/KR102190087B1/ko active IP Right Grant
- 2013-11-15 PL PL13789833T patent/PL2925761T3/pl unknown
- 2013-11-15 MA MA38099A patent/MA38099B1/fr unknown
- 2013-11-15 WO PCT/EP2013/073946 patent/WO2014076237A1/en active Application Filing
- 2013-11-15 AP AP2015008418A patent/AP2015008418A0/xx unknown
- 2013-11-15 TW TW102141767A patent/TWI619717B/zh active
- 2013-11-15 ME MEP-2017-190A patent/ME02857B/me unknown
- 2013-11-15 UY UY0001035142A patent/UY35142A/es not_active Application Discontinuation
- 2013-11-15 HU HUE13789833A patent/HUE034467T2/en unknown
- 2013-11-15 SI SI201330773T patent/SI2925761T1/sl unknown
- 2013-11-15 LT LTEP13789833.4T patent/LT2925761T/lt unknown
- 2013-11-15 GE GEAP201313859A patent/GEP201706624B/en unknown
- 2013-11-15 MY MYPI2015001310A patent/MY191358A/en unknown
- 2013-11-15 AU AU2013346809A patent/AU2013346809B9/en active Active
- 2013-11-15 EP EP13789833.4A patent/EP2925761B1/en active Active
- 2013-11-15 UA UAA201505745A patent/UA114739C2/uk unknown
- 2013-11-15 ES ES13789833.4T patent/ES2641465T3/es active Active
- 2013-11-15 BR BR112015011158-0A patent/BR112015011158B1/pt active IP Right Grant
- 2013-11-15 AR ARP130104230A patent/AR093515A1/es active IP Right Grant
- 2013-11-15 SG SG11201503856XA patent/SG11201503856XA/en unknown
- 2013-11-15 RS RS20170907A patent/RS56333B1/sr unknown
- 2013-11-15 PE PE2015000635A patent/PE20151023A1/es active IP Right Grant
- 2013-11-15 CA CA2891193A patent/CA2891193C/en active Active
- 2013-11-15 CN CN201710479950.0A patent/CN107266455B/zh active Active
-
2015
- 2015-04-21 IL IL238400A patent/IL238400A/en active IP Right Grant
- 2015-05-08 CL CL2015001250A patent/CL2015001250A1/es unknown
- 2015-05-14 TN TNP2015000187A patent/TN2015000187A1/fr unknown
- 2015-05-14 PH PH12015501074A patent/PH12015501074B1/en unknown
- 2015-11-09 HK HK15111012.4A patent/HK1210169A1/xx unknown
-
2016
- 2016-01-14 US US14/995,578 patent/US10328074B2/en active Active
-
2017
- 2017-09-26 CY CY20171101012T patent/CY1119387T1/el unknown
- 2017-10-02 HR HRP20171474TT patent/HRP20171474T1/hr unknown
-
2019
- 2019-04-19 US US16/389,062 patent/US11077107B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR093515A1 (es) | Triazolopirazinas | |
AR119454A2 (es) | COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO | |
AR090868A1 (es) | Composiciones plaguicidas y procesos relacionados con ellas | |
AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
ECSP11010912A (es) | Compuestos de pirrol | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR093767A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona y profarmacos de estos | |
AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
AR094351A1 (es) | Picolinamidas macrocíclicas como fungicidas | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR091498A1 (es) | DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
CR20150268A (es) | Compuestos novedosos | |
MX2015015786A (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas. | |
ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
AR098270A1 (es) | Poliéster terminado en epoxi | |
AR099646A1 (es) | Fotoestabilizantes de aminas impedidas | |
AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
AR093503A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
AR097252A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
AR101479A1 (es) | Derivados de 6-alquinil-piridina | |
AR097245A1 (es) | Derivado de pirazolilpirazol sustituido y su empleo como herbicida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |